🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

16 results for “Madrigal Pharmaceuticals EU Limited” Clear

  1. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    NASH - Nonalcoholic Steatohepatitis

    phase 3 small molecule active

    1 trial

  2. MGL-3196 80 mg oral, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 60 mg film-coated tablet, MGL-3196 60 mg oral, MGL-3196 100 mg oral, Matching placebo MGL-3196 100 mg film-coated tablet

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis (NASH) Cirrhosis

    phase 3 small molecule active

    1 trial

  3. Matching placebo MGL-3196 60 mg film-coated tablet, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 100 mg film-coated tablet., MGL-3196 60 mg oral, MGL-3196 100 mg oral, MGL-3196 80 mg oral

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  4. Placebo

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Fatty Liver Disease

    phase 3 small molecule completed

    1 trial

  5. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    NASH

    phase 3 small molecule active

    1 trial

  6. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Fatty Liver Disease

    phase 3 small molecule active

    1 trial

  7. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  8. MGL-3196 (resmetirom)

    Madrigal Pharmaceuticals EU Limited

    Heterozygous Familial Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  9. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    MASH - Metabolic Dysfunction-Associated Steatohepatitis

    phase 2 small molecule active

    1 trial

  10. 100 mg Resmetirom Tablet

    Madrigal Pharmaceuticals EU Limited

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  11. Atorvastatin

    Madrigal Pharmaceuticals EU Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  12. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  13. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    Healthy

    phase 1 small molecule completed

    3 trials

  14. MGL-3196 Tablet

    Madrigal Pharmaceuticals EU Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  15. Placebo

    Madrigal Pharmaceuticals EU Limited

    Drug Safety

    phase 1 small molecule completed

    2 trials

  16. Simvastatin

    Madrigal Pharmaceuticals EU Limited

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources